23 November 2022
Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)
Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development.
This nomination decision was unanimous following review of pharmaceutical development and pre-clinical data, which demonstrated the required drug attributes to progress towards regulatory advice and then clinical trials. The nomination of BB1511 followed on from the development of BB0107, which although did not quite meet our high standards for nomination, provided valuable insight to allow us to adapt the formulation development for BB1511.
BB1511 is a light cream formulation designed to support skin barrier function whilst reducing the inflammation associated with atopic dermatitis, which we hope will help many patients in managing their disease more effectively.
BB1511 adds to our expanding drug portfolio in the clinical phase (alongside BB2603 for onychomycosis and BB1202 for tinea pedis).